Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Hattersley Larralde
Drug resistance has emerged as a formidable challenge in modern healthcare, posing significant threats to the effectiveness of treatments across various medical disciplines. This paper examines the multifaceted problem of drug resistance, encompassing its molecular mechanisms, epidemiological factors, and clinical implications. We delve into the pivotal role of microbial organisms, such as bacteria and viruses, in driving antibiotic and antiviral resistance, as well as the genetic and adaptive processes that underlie this phenomenon. Furthermore, we explore how drug resistance extends beyond infectious diseases to encompass cancer and other non-communicable diseases, complicating therapeutic strategies. The socio-economic dimensions of drug resistance are also considered, highlighting the economic burdens and healthcare disparities it engenders. In response, this paper proposes a comprehensive approach involving enhanced surveillance, novel drug development, optimized treatment protocols, and public education. By rising to the challenge of drug resistance, the modern healthcare landscape can safeguard the efficacy of existing treatments and ensure better health outcomes for patients worldwide.